5 Jun 2017 17:36
For immediate release
Circassia Pharmaceuticals plc
Persons Discharging Managerial Responsibilities and persons closely associated with them notification
Oxford, UK - 5 June 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR) Persons Discharging Managerial Responsibilities and persons closely associated with them notification.
This form is for the use of persons discharging managerial responsibilities (PDMRs) as well as persons closely associated with them to notify transactions to the FCA under Article 19(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("The Market Abuse Regulation").
Once this form has been sent to the designated email address, it constitutes the "secure means of transmission" mandated in Article 2 of Regulation (EU) 2016/523. PDMRs as well as persons closely associated with them are required to use this form when submitting a notification under this article.
PDMR Notification Form Page
1 - Details of the person discharging managerial responsibilities/person closely associated
Name of natural person* | Jean Jacques Garaud |
2 - Reason for the notification
Position/status* | Non-Executive Director (PDMR) |
Initial notification/amendment* | Initial Notification |
In case of amendment, please enter the previous notification reference number and explain the error that this notification needs amending | N/A |
3 - Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Full name of entity* | Circassia Pharmaceuticals plc |
Legal Entity Identifier code | 2138006YAT138TOGA556 |
In accordance with ISO 1744 LEI code |
4 - Details of the transaction(s)
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
Date | Description of Financial Transaction | Aggregated Price | Aggregated Volume | Total Aggregated Price |
02-Jun-17 | Exercise of options | £0.0008 | 77,500 | £62.00 |
02-Jun-17 | Sale of shares | £0.8911 | 77,500 | £69,060.25 |
i. Exercise of options
Description of the financial instrument, type of instrument* | Circassia Holdings Ltd 2007 Unapproved Option Scheme | ||||||
Identification Code* | GB00BJVD3B28 | ||||||
Nature of the transaction* | Exercise of options | ||||||
Currency* | GBP | ||||||
Price(s) and Volume (s) |
| ||||||
Aggregated Information |
| ||||||
Date of Transaction* | 2 June 2017 | ||||||
Place of Transaction* | London: XLON |
ii. Sale of shares following exercise of options
Description of the financial instrument, type of instrument* | Circassia Holdings Ltd 2007 Unapproved Option Scheme | ||||||
Identification Code* | GB00BJVD3B28 | ||||||
Nature of the transaction* | Sale of shares | ||||||
Currency* | GBP | ||||||
Price(s) and Volume (s) |
| ||||||
Aggregated Information |
| ||||||
Date of Transaction* | 2 June 2017 | ||||||
Place of Transaction* | London: XLON |
-Ends-
For further information, please contact: | |
Circassia Pharmaceuticals plc Julien Cotta, Company Secretary |
+44 (0) 1865 405560 |